GRIFOLS SA-ADR (GRFS)
US3984384087 - ADR
Wednesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to...
INVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - August 31, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
INVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Grifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - August 29, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Grifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Grifols SA Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - August 27, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Grifols SA Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GRFS Crosses Above Key Moving Average Level
Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again – Hagens Berman
GRFS Is Being Investigated for Potential Securities Law Violations Contact Kaplan Fox & Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - August 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
GRFS Is Being Investigated for Potential Securities Law Violations Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox & Kilsheimer LLP is Investigating Possible Securities Law Violations against Grifols SA (GRFS)
NEW YORK, NY - (NewMediaWire) - July 31, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Kaplan Fox & Kilsheimer LLP is Investigating Possible Securities Law Violations against Grifols SA (GRFS)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox & Kilsheimer LLP is Investigating Grifols SA (GRFS) for Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - July 30, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Kaplan Fox & Kilsheimer LLP is Investigating Grifols SA (GRFS) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to...
3 Stocks to Buy From the ‘Ultimate’ Buy-and-Hold Portfolio
Finding stocks to buy and hold for the long haul is sometimes as easy as grabbing a few suggestions from a seasoned investment pro.
GRFS Stock Alert: Grifols Pops 20% on Takeover Interest
Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares.
GRFS Stock Alert: Grifols Pops 20% on Takeover Interest
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Grifols (NASDAQ:GRFS) stock is jumping on Monday after investors learned that t...
GRFS Makes Bullish Cross Above Critical Moving Average
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to know about on Monday!
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo...
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that...
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo,...
Grifols 2023 Annual Report on Form 20-F filed with the SEC
/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...